Scanning research now

AI-Powered
Deep Tech
Deal Sourcing.

Conduit scans ArXiv, USPTO, and academic labs 24/7 to surface investment opportunities before they become startups — and writes the memo for you.

Request Demo → View pricing →

No credit card required  ·  Setup in 24 hours

5 Sources Scanned Daily
43+ Papers Tracked
12+ High-Score Opportunities
24/7 Autonomous Monitoring

Deep-tech VCs spend weeks reading papers, attending conferences, and working their networks to find deals. They still miss most of them. The best science never makes it to a pitch deck.

Research Scanner

Continuously monitors ArXiv, PubMed, USPTO, and university tech transfer offices. Identifies commercializable breakthroughs as they're published.

AI Deal Scorer

Evaluates every discovery on market size, IP strength, team quality, and reproducibility. Returns a ranked pipeline, not a reading list.

Memo Generator

Produces investment-grade deal memos with thesis, risk analysis, and comparable exits — complete with commercialization pitch. Ready for Monday partner meeting.

Patent Tracker

Tracks USPTO filings and portfolio company publications. Spots IP inflection points, continuation filings, and defensive patterns before they move markets.

See it running on your thesis areas.

We'll send a sample memo built from your deal flow within 24 hours.
Request a Demo →
What lands in your inbox every morning

Real scored paper card + auto-generated deal memo. No editorial, no curation lag.

arXiv · cs.LG
8.7
/ 10 score
Adaptive Protein Folding Accelerators for On-Device Drug Screening at Sub-Millisecond Latency
MIT CSAIL · Chen et al. · Feb 2025 · 4 citations in 3 weeks
Biotech Hardware Patent Pending
Market Size
IP Strength
Team Signal
Reproducibility
Auto-Generated Deal Memo Conduit AI
Investment Thesis

On-device protein folding at <1ms latency eliminates cloud dependency for real-time drug screening. Addressable market: $14B in computational drug discovery tools by 2028. First hardware-software co-design approach with pending IP moat.

Commercialization Path

License to pharma majors (Pfizer, Roche) for preclinical pipelines, or spin out as inference chip + API (NVIDIA inference play analogue). MIT TTO contact: available via Conduit outreach tool.

Key Risks & Signals
3 provisional patents filed NIH Phase II grant ($2.4M) No industry co-authors yet Benchmark reproducibility unverified
Comparable Exits

Recursion Pharmaceuticals (IPO $900M), D.E. Shaw Research (acquisition by Relay Therapeutics), Insilico Medicine ($95M Series D).

Early Access
A fraction of what you're
paying for less coverage.

Full pipeline: daily scans, AI scoring, deal memos, patent tracking. No analyst headcount. No conference tickets. No missed deals.

$300
to $1K / month
vs. $12,000+/year incumbents
(Vertical IQ, CB Insights, AlphaSense)
View Plans →

Manual Sourcing

Read 200 papers to find 3 worth exploring
Network-dependent pipeline limits diversity
Due diligence takes weeks per opportunity
Miss breakthroughs outside your subfield
Patent filings discovered months late

With Conduit

Ranked pipeline of scored opportunities, daily
Every lab, every field, every geography
AI-generated memos ready for partner review
Cross-domain discoveries surface automatically
USPTO filings tracked the day they're published
Early Access

Request a
Personalized Demo

See Conduit running on your actual thesis areas. We'll set up a live walkthrough and send you a sample memo from your deal flow within 24 hours.

You're in the queue.

We'll reach out within 24 hours with a personalized demo — including a sample memo built from your thesis areas.

Request a Demo →